Solos Jaturapisanukul

Nephrologist at Vajira Hospital @VJRnephro , Research Fellow Mayo Clinic @MayoClinicNeph , MTG player @wizards_magic , Owner of Penguin's cardgame

[NDT @NDTsocial]

🧐Editor's choice from June issue NDT:

Biology of drug-induced acute nephrotoxicity: focus on the tubulointerstitium

🆓https://t.co/6KTmGwFS24

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[CKJ @CKJsocial]

Executive summary of the European consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance

https://t.co/kXkfPZwg0J

[Wisit Cheungpasitporn MD FACP | FASN | FAST @wisit661]

😃Honored to share our new collaborative study published in the Journal of Nephrology! 🎓💻
“Comparison of human vs AI-generated feedback: results from an online survey study in the GlomCon glomerular disease fellowship program.”

🔗 Read the full article here: https://t.co/oEkL2xEhNn

What happens when we directly compare AI-generated educational feedback to human-generated feedback in advanced medical training? In this study, we explored how learners perceived both approaches across several critical domains.

💡 Key Findings:
We discovered that AI-generated feedback performed comparably to human-generated feedback across multiple learner-centered outcomes, including:
🔹 Fairness
🔹 Constructiveness
🔹 Supportiveness
🔹 Utility for Improvement

The Big Picture: As generative AI continues to rapidly evolve within nephrology and academic medicine, its role is not to replace human mentorship, but to augment it. Thoughtful evaluation of how AI can enhance education and deliver structured, timely feedback will become increasingly vital in fellowship training.

😃 I am incredibly grateful to collaborate with such an outstanding team at the intersection of nephrology, education, and responsible AI implementation: Niloufar Ebrahimi , Zohreh Gholizadeh Ghozloujeh, Lawrence K. Loo, Pravir Baxi, Zhabiz Solhjou, Arun Rajasekaran, Zainab Obaidi, Arvind Singh, Rica Mae Pitogo, and Sayna Norouzi MD . 🤝✨@n0r0zha @SaynaNorouzi @MayoClinicNeph

🔗 Read the full article here: https://t.co/oEkL2xEhNn

Wisit Cheungpasitporn, MD, FACP, FASN, FAST
Professor of Medicine & Clinician-Scientist, Mayo Clinic

Leading AI Innovation in Kidney Care & Medical Education
#AIinMedicine #MedicalEducation #Nephrology #ArtificialIntelligence #GenerativeAI #GlomCon #DigitalHealth #KidneyEducation #MedEd #KidneyCare #FutureOfMedicine

[Solos Jaturapisanukul @SolosVJR]

@AntiCigV2 @laongroong ใจเย็นๆ ดีกว่าครับ ชีวิตจริงก็เคยเจอพยบ พยายามเซฟแพทย์บ่อยครับ ถ้าเขียนเป็น notify แพทย์ เวลา... แพทย์ไม่มาดู พอเป็นเคสคดีจะมีปัญหา อีกอย่างรพช เล็กๆ สถานะพยบกับแพทย์ไม่เหมือนรรพ หรือ รพท ครับ

[Solos Jaturapisanukul @SolosVJR]

Which one is more likely to represent MGRS pspectrum ?

1. Monotypic DNAJB9 positive Fibrillary GN

2. Membranous-like glomerulopathy with Masked IgGK deposits

3. PGNMID IgG3 variants

4. Light chain cast nephropathy

5. Non-hepatitis Seronegative Type 2 Cryoglobulinemic GN

[Wisit Cheungpasitporn MD FACP | FASN | FAST @wisit661]

😊🙏🏻Excited to share our new publication in American Journal of Kidney Diseases:
@AJKDonline

“Deceased Donor Kidney Transplantation Versus Continued Dialysis Among Patients Aged 75 Years or Older: A Target Trial Emulation.”

https://t.co/ZzSVe1eO6T

This study addresses a clinically important and increasingly common question in nephrology and transplant medicine:
Should carefully selected adults ≥75 years old remain on dialysis or pursue deceased donor kidney transplantation?

Using a target trial emulation framework with sequential trials methodology, we analyzed outcomes among transplant-eligible older adults listed in the OPTN registry from 2015–2023.

Key findings:

* Kidney transplantation in adults ≥75 years was associated with an early postoperative mortality risk during the first 90 days.
* Survival benefit emerged gradually over time, with a break-even point around 3 years.
* By 5 years, deceased donor kidney transplantation conferred an approximately 111-day survival advantage compared with remaining on dialysis.
* Findings support individualized decision-making rather than a one-size-fits-all approach for older transplant candidates.

Importantly, the study highlights that dialysis may remain a reasonable alternative for some older adults, particularly when considering frailty, symptom burden, quality of life, and competing risks.

Congratulations to all co-authors and collaborators on this important work in advancing evidence-based care for older adults with kidney failure.

Authors: Napat Leeaphorn, Rose Mary Attieh, Katherine M. Oshel, Oscar A. Garcia Valencia, Wisit Cheungpasitporn, Tambi Jarmi, and colleagues.

@napatlee1 @OscarGarciaMD @MayoClinicNeph

📍
National Kidney Foundation @nkf

#Nephrology #KidneyTransplant #Transplantation #Dialysis #KidneyDisease #AJKD #TargetTrialEmulation #ClinicalResearch #ESKD #KidneyCare

[Sayed S Rahman @SayedSRahman1]

Approach to Non-Albumin predominant proteinuria .

Suspect when
- There is discrepancy between dipstick and 24hr proteinuria or
- UACR not making predominant part of UPCR .

[Nature Reviews Nephrology @NatRevNeph]

Gene–disease relationships for glomerular phenotypes: expert recommendations from ClinGen https://t.co/1mKtdYLrX7

[American Society of Onconephrology @onconephsociety]

Don’t miss the upcoming @onconephsociety educational seminar on MGRS and PGNMID.

Friday, May 22, 12 PM EDT 2026.

[soda_troubles, I have faith in Discord. @set_fortess]

Renal Manifestations in VEXAS Syndrome: A Systematic Review of Clinical Features, Pathology, and Outcomes
https://t.co/Qck9dg7aLm

[Dr. Divya Bajpai 🇮🇳 @divyaa24]

The forever dilemma - CM -tma versus malignant HTN
@GlomCon by Dr sharon Ford

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Consensus Recommendation: Real World Insights on Attitudes and Treatment of Hyperkalemia ca. 2026 from @MayoProceedings @RPANephrology @GarySingerMD
#Nephpearls

👉 https://t.co/qBWATmz0bL
👉 https://t.co/2qRpZmP9qj

[Peritoneal Dialysis International Journal @PDI_Journal]

Thailand's dialysis policy evolution and the "success paradox" of modality choice reforms. 🇹🇭
https://t.co/XfYe3hM9OW

[CKJ @CKJsocial]

Nutcracker syndrome in 2026:

a nephrologist-oriented diagnosis and management

https://t.co/XdKf49UB8D

[Solos Jaturapisanukul @SolosVJR]

@pizad_sura 1. เคยมีคนไข้เบาหวานกินน้ำหวานบ่อยจนน้ำตาลพุ่ง เพราะหมอบอกว่าเคยเป็นโรคเฮลบลูบอย สรุป คนไข้เป็นโรคเมลิออยด์ - -“

2. เคยรายงานหน้าชั้นเรียนว่าคนไข้มีภาวะ unstable vagina

3. เคยแจ้งว่าคนไข้หัวใจผิดปกติ (+murmur) คนไข้บอกว่าเพิ่งอกหักมา หัวใจเลยแย่

[Solos Jaturapisanukul @SolosVJR]

@manopsi พีคสุดคือแก่สุดเป็นนักวิจัยเนี่ยแหละครับอจ 55

[Solos Jaturapisanukul @SolosVJR]

Hairy Kidney Sign 😆

Erdheim-Chester disease

[ASN Publications @asnpublications]

Which is a better treatment for people with hyperkalemia: sodium zirconium cyclosilicate (SZC) or patiromer? That depends. Find out why in the #ASNKidney360 study. https://t.co/RYsFq2uuZD

[Karan Singhal @thekaransinghal]

Today we’re introducing two big steps for health at OpenAI:

- ChatGPT for Clinicians, a free version of ChatGPT designed for clinical work
- HealthBench Professional, a new benchmark to evaluate real clinician chat tasks

We’re excited about what this can unlock for care. ❤️